Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine Differentiation - Trial NCT06414915
Access comprehensive clinical trial information for NCT06414915 through Pure Global AI's free database. This Phase 2 trial is sponsored by National Cancer Center, China and is currently Not yet recruiting. The study focuses on NSCLC. Target enrollment is 29 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
National Cancer Center, China
Timeline & Enrollment
Phase 2
Jun 01, 2024
Jun 01, 2027
Primary Outcome
Progression-Free Survival (PFS)
Summary
Currently, there are no standard treatment and relevant exploration for NSCLC patients with
 NED. The study aims to explore the efficacy and safety of surufatinib combined with
 tislelizumab in the treatment of NSCLC with NED, in order to provide a new treatment option
 for NSCLC patients with NED.
Data Source
ClinicalTrials.gov
NCT06414915
Non-Device Trial